摘要

Diabetic cardiomyopathy is a major complication of diabetes mellitus (DM). Currently, effective treatments for diabetic cardiomyopathy are limited. The pathophysiology of diabetic cardiomyopathy is complex, whereas mitochondrial dysfunction plays a vital role in the genesis of diabetic cardiomyopathy. Metabolic regulation targeting mitochondrial dysfunction is expected to be a reasonable strategy for treating diabetic cardiomyopathy. Peroxisome proliferator-activated receptors (PPARs) are master executors in regulating glucose and lipid homeostasis and also modulate mitochondrial function. However, synthetic PPAR agonists used for treating hyperlipidemia and DM have shown controversial effects on cardiovascular regulation. This article reviews our updated understanding of the beneficial and detrimental effects of PPARs on mitochondria in diabetic hearts.
原文英語
文章編號5
期刊Journal of Biomedical Science
24
發行號1
DOIs
出版狀態已發佈 - 一月 10 2017

指紋

Diabetic Cardiomyopathies
Peroxisome Proliferator-Activated Receptors
Medical problems
Metabolism
Mitochondria
Lipids
Glucose
Diabetes Complications
Hyperlipidemias
Diabetes Mellitus
Homeostasis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

引用此文

@article{23425a236a30439a98c26427ddc23fdb,
title = "PPARs modulate cardiac metabolism and mitochondrial function in diabetes",
abstract = "Diabetic cardiomyopathy is a major complication of diabetes mellitus (DM). Currently, effective treatments for diabetic cardiomyopathy are limited. The pathophysiology of diabetic cardiomyopathy is complex, whereas mitochondrial dysfunction plays a vital role in the genesis of diabetic cardiomyopathy. Metabolic regulation targeting mitochondrial dysfunction is expected to be a reasonable strategy for treating diabetic cardiomyopathy. Peroxisome proliferator-activated receptors (PPARs) are master executors in regulating glucose and lipid homeostasis and also modulate mitochondrial function. However, synthetic PPAR agonists used for treating hyperlipidemia and DM have shown controversial effects on cardiovascular regulation. This article reviews our updated understanding of the beneficial and detrimental effects of PPARs on mitochondria in diabetic hearts.",
keywords = "Cardiomyopathy, Diabetes mellitus, Metabolism, Mitochondria, Peroxisome proliferator-activated receptors",
author = "Lee, {Ting Wei} and Bai, {Kuan Jen} and Lee, {Ting I.} and Chao, {Tze Fan} and Kao, {Yu Hsun} and Chen, {Yi Jen}",
year = "2017",
month = "1",
day = "10",
doi = "10.1186/s12929-016-0309-5",
language = "English",
volume = "24",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - PPARs modulate cardiac metabolism and mitochondrial function in diabetes

AU - Lee, Ting Wei

AU - Bai, Kuan Jen

AU - Lee, Ting I.

AU - Chao, Tze Fan

AU - Kao, Yu Hsun

AU - Chen, Yi Jen

PY - 2017/1/10

Y1 - 2017/1/10

N2 - Diabetic cardiomyopathy is a major complication of diabetes mellitus (DM). Currently, effective treatments for diabetic cardiomyopathy are limited. The pathophysiology of diabetic cardiomyopathy is complex, whereas mitochondrial dysfunction plays a vital role in the genesis of diabetic cardiomyopathy. Metabolic regulation targeting mitochondrial dysfunction is expected to be a reasonable strategy for treating diabetic cardiomyopathy. Peroxisome proliferator-activated receptors (PPARs) are master executors in regulating glucose and lipid homeostasis and also modulate mitochondrial function. However, synthetic PPAR agonists used for treating hyperlipidemia and DM have shown controversial effects on cardiovascular regulation. This article reviews our updated understanding of the beneficial and detrimental effects of PPARs on mitochondria in diabetic hearts.

AB - Diabetic cardiomyopathy is a major complication of diabetes mellitus (DM). Currently, effective treatments for diabetic cardiomyopathy are limited. The pathophysiology of diabetic cardiomyopathy is complex, whereas mitochondrial dysfunction plays a vital role in the genesis of diabetic cardiomyopathy. Metabolic regulation targeting mitochondrial dysfunction is expected to be a reasonable strategy for treating diabetic cardiomyopathy. Peroxisome proliferator-activated receptors (PPARs) are master executors in regulating glucose and lipid homeostasis and also modulate mitochondrial function. However, synthetic PPAR agonists used for treating hyperlipidemia and DM have shown controversial effects on cardiovascular regulation. This article reviews our updated understanding of the beneficial and detrimental effects of PPARs on mitochondria in diabetic hearts.

KW - Cardiomyopathy

KW - Diabetes mellitus

KW - Metabolism

KW - Mitochondria

KW - Peroxisome proliferator-activated receptors

UR - http://www.scopus.com/inward/record.url?scp=85008668630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008668630&partnerID=8YFLogxK

U2 - 10.1186/s12929-016-0309-5

DO - 10.1186/s12929-016-0309-5

M3 - Review article

C2 - 28069019

AN - SCOPUS:85008668630

VL - 24

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 5

ER -